Expects to Announce Results of Meeting After Receipt of Final Minutes from FDA PRINCETON, N.J. , Dec. 13, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq: AGRX), a women’s healthcare company, today announced that on December 11, 2018 , it met with the U.S....
PRINCETON, N.J. , Dec. 18, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced today that its Chairman and Chief Executive Officer, Al Altomari will present at the Biotech Showcase 2019 on Tuesday January 8, 2019 at 10:00 AM Pacific...
Discussions with FDA on Design of Comparative Wear Study of Twirla ® and Xulane ® Completed Cash Expected to Enable Company to Fund Operations into Second Quarter of 2019 PRINCETON, N.J. , Jan. 10, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq: AGRX), a women’s healthcare company,...
PRINCETON, N.J. , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced today that its Chairman and Chief Executive Officer, Al Altomari will present at the 2019 BIO CEO & Investor conference on Tuesday February 12, 2019 at 10:30 AM...
Company now focused on completing plan to resubmit NDA in first half of 2019. PRINCETON, N.J., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq: AGRX), a women’s healthcare company, today announced topline results from a comparative wear study testing the...
PRINCETON, N.J. , March 04, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, announced today that it has entered into a definitive stock purchase agreement with Perceptive Advisors, LLC , for the private placement of approximately 8.4 million shares...
PRINCETON, N.J. , March 11, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced today that its Senior Vice President and Chief Financial Officer, Scott Coiante will present at Oppenheimer’s 29 th Annual Healthcare Conference on Tuesday March...
Cash Expected to Enable Company to Fund Operations into the Fourth Quarter of 2019 Company plans to resubmit Twirla NDA in second quarter of 2019 PRINCETON, N.J. , March 12, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported financial...
PRINCETON, N.J. , March 15, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq: AGRX), a women's healthcare company, today announced that an abstract presenting data from two Phase 1 in vivo wear studies on the adhesion of Twirla ® has been selected for a poster presentation during the 2...
PRINCETON, N.J. , March 28, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced today that its Chairman and Chief Executive Officer, Al Altomari will present at the H.C. Wainwright Global Life Sciences conference on Monday April 8, 2019 at...